Metabolic Therapeutics

Search documents
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
Globenewswireยท 2025-06-18 11:00
Core Insights - Fractyl Health, Inc. has strengthened its intellectual property portfolio with the issuance of two new U.S. patents, enhancing its leadership in metabolic innovation and duodenal resurfacing technologies [1][2][3] Intellectual Property Developments - The company has built a robust patent portfolio since 2011, now comprising 31 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign patents [2][5] - The newly issued patents focus on electrical energy ablation systems for treating tissue, specifically targeting duodenal mucosa with thermal and non-thermal energy applications [3][4] Product and Clinical Development - Fractyl's lead product candidate, Revita, aims to remodel the duodenal lining to reverse damage caused by high-fat and high-sugar diets, which are root causes of metabolic diseases [6][7] - Revita has received U.S. FDA Breakthrough Device designation for weight maintenance in patients who discontinue GLP-1-based drugs [6][7] - The company is preparing for three key data readouts from its pivotal study of Revita, with significant milestones expected in June 2025, Q3 2025, and the second half of 2026 [4][5]